Clinical Trials
Risk Factors for Acute Idiopathic
Transverse Myelitis Principal Investigator – Dr. Neal Halsey
Study Number – 268
Johns Hopkins is currently enrolling new and recently diagnosed patients with idiopathic acute transverse myelitis (IATM) to study risk factors for the disease. This is a study conducted in collaboration with investigators at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Transverse Myelitis Center, under the auspices of the Centers for Disease Control and Prevention. In this exploratory study, patients will be asked to complete a questionnaire detailing demographic, socioeconomic data, information regarding illness and underlying diseases, medications, immunizations, travel history and other physician visits in the preceding 24 months prior to the onset of idiopathic acute TM.
| Interested patients should contact the study coordinators: |
| | Yandong Qiang |
410.955.2955 |
| | Chitra Krishnan |
410.955.3129 |
| | Rosanna Setse |
410.614.7797 |
| | Megan Quigg |
410.955.3129 |
| | Douglas Kerr |
410.955.3129 |
| | Neal Halsey |
410.955.6964 |
The Use of Magnetic Resonance Spectroscopy and Cytokine Measurements
to Investigate Depression in Autoimmune Neurologic Diseases
Principal
Investigator: Adam Kaplin, MD/PhD
Registered Protocol Number: 03-07-03-09
Johns Hopkins is currently enrolling TM, MS and non-autoimmune myelopathy patients
in a prospective study (6 months follow-up) to investigate the epidemiology
of cytokine-mediated depression and cognitive impairment in TM subjects compared
to MS and non-autoimmune myelopathy controls.
Subjects will be followed longitudinally
to determine if changes in cytokine levels and brain metabolites parallel changes
in mood, cognition and neurologic outcomes. Acute new onset TM and MS patients
between the ages of 18-65 years will be enrolled in this study.
Interested
patients should contact the study coordinator, Samantha Bartner, at 410.502.2574
for more information.
High Dose Cyclophosphamide in the Treatment of Aggressive Multiple
Sclerosis
Principal Investigator: Douglas A. Kerr, MD/PhD
Registered Protocol Number: 03-06-05-05
Johns Hopkins is currently enrolling MS patients for a clinical trial evaluating
the safety and effectiveness of high dose cyclophosphamide.
Patients in the
two-year study need to have aggressive relapsing-remitting MS, must be unable
to tolerate or have failed to optimally respond to conventional therapy (Avonex,
Betseron, Copaxone, Rebif) and are at high risk of disease progression and
loss of function.
Interested patients should contact the study coordinator,
Chitra Krishnan, at 410.955.3129 for more information.
